Manuel S. Eisenberg
- Oct 9, 2020
- 1 min read

UroLift continues to do well in "real world" studies

Results of UroLift were evaluated in a group of 2000 patients. Of these patients, 153 required some type of intervention during follow up. The overall reintervention rate was calculated at 6% per year. Of the 153 patients undergoing a secondary procedure, approximately half moved on to TURP, 1/3 underwent repeat UroLift, and less than 20% had their UroLift implants removed. An overall success rate of 94% per year, coupled with the minimally invasive procedure and the ability to further treat minimally invasively if needed, I believe solidifies UroLift as the "go-to" initial treatment for men with significant lower urinary tract symptoms.

https://pubmed.ncbi.nlm.nih.gov/32396049/

Recent Posts

See All

Sexual function is a significant consideration when undergoing treatment for BPH

The majority of men over 50 years old have some degree of urinary symptoms due to an enlarge prostate. Both medications and surgery for the treatment of these symptoms can have side effects, includin

UroLift performs better than Rezume in the “real world”

A recent study compared the early outcomes of UroLift (prostatic urethral lift) versus Rezume (prostate steam therapy) in patients in the community/”real work” setting. The early outcomes show superi

UroLift updates in the BPH guidelines

UroLift (prostatic urethral lift) is a featured management in the treatment of enlarged prostate/BPH. Recent American Urologic Association guidelines were amended highlighting the appropriateness and